XAIR Beyond Air, Inc.

Nasdaq beyondair.net


$ 2.73 $ 0.07 (2.66 %)    

Tuesday, 14-Oct-2025 18:55:31 EDT
QQQ $ 598.50 $ -4.01 (-0.67 %)
DIA $ 463.08 $ 2.03 (0.44 %)
SPY $ 662.74 $ -0.81 (-0.12 %)
TLT $ 90.69 $ 0.29 (0.32 %)
GLD $ 382.95 $ 2.70 (0.71 %)
$ 2.7
$ 2.63
$ 2.49 x 300
$ 2.80 x 104
$ 2.52 - $ 2.72
$ 2.02 - $ 13.52
215,206
na
14.11M
$ 0.92
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-12-2025 06-30-2025 10-Q
2 06-20-2025 03-31-2025 10-K
3 02-10-2025 12-31-2024 10-Q
4 11-12-2024 09-30-2024 10-Q
5 08-06-2024 06-30-2024 10-Q
6 06-24-2024 03-31-2024 10-K
7 02-12-2024 12-31-2023 10-Q
8 11-13-2023 09-30-2023 10-Q
9 08-10-2023 06-30-2023 10-Q
10 06-22-2023 03-31-2023 10-K
11 02-10-2023 12-31-2022 10-Q
12 11-08-2022 09-30-2022 10-Q
13 08-11-2022 06-30-2022 10-Q
14 06-28-2022 03-31-2022 10-K
15 02-10-2022 12-31-2021 10-Q
16 11-12-2021 09-30-2021 10-Q
17 08-10-2021 06-30-2021 10-Q
18 06-10-2021 03-31-2021 10-K
19 02-09-2021 12-31-2020 10-Q
20 11-12-2020 09-30-2020 10-Q
21 08-06-2020 06-30-2020 10-Q
22 06-23-2020 03-31-2020 10-K
23 02-07-2020 12-31-2019 10-Q
24 11-06-2019 09-30-2019 10-Q
25 08-14-2019 06-30-2019 10-Q
26 06-28-2019 03-31-2019 10-K
27 02-14-2019 12-31-2018 10-Q
28 11-14-2018 09-30-2018 10-Q
29 08-14-2018 06-30-2018 10-Q
30 03-30-2018 12-31-2017 10-K
31 11-03-2017 09-30-2017 10-Q
32 08-11-2017 06-30-2017 10-Q
33 05-15-2017 03-31-2017 10-Q
34 03-31-2017 12-31-2016 10-K
35 11-14-2016 09-30-2016 10-Q
36 10-13-2016 06-30-2016 10-K
37 05-12-2016 03-31-2016 10-Q
38 02-23-2016 12-31-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 beyond-air-exercises-outstanding-common-warrants-for-gross-proceeds-of-325m-through-immediate-exercise-of-144m-warrants-at-221share-issues-720k-new-warrants-at-00625-with-5-year-term

Beyond Air, Inc.

 beyond-air-granted-orphan-designation-status-for-7-nitro-1h-indazole-for-the-treatment-of-malignant-glioma

https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=1091925

 d-boral-capital-maintains-buy-on-beyond-air-maintains-11-price-target

D. Boral Capital analyst Jason Kolbert maintains Beyond Air (NASDAQ:XAIR) with a Buy and maintains $11 price target.

 d-boral-capital-maintains-buy-on-beyond-air-maintains-11-price-target

D. Boral Capital analyst Jason Kolbert maintains Beyond Air (NASDAQ:XAIR) with a Buy and maintains $11 price target.

 beyond-air-affirms-fy2026-sales-guidance-of-1200m-1600m-vs-1332m-est

Beyond Air (NASDAQ:XAIR) affirms FY2026 sales outlook from $12.00 million-$16.00 million to $12.00 million-$16.00 million vs $1...

 beyond-air-q1-eps-153-misses-007-estimate-sales-176m-beat-175m-estimate

Beyond Air (NASDAQ:XAIR) reported quarterly losses of $(1.53) per share which missed the analyst consensus estimate of $(0.07) ...

 beyond-air-awarded-national-group-purchasing-agreement-for-therapeutic-gases-with-premier-inc

Beyond Air, Inc. (NASDAQ:XAIR) ("Beyond Air" or the "Company"), a commercial stage medical device and biopharma...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION